Yungjin Pharm KRX:003520KOSPI
영진약품 · Korean news coverage and regulatory filings, organized.
Articles, 24h1
Articles, 7 days1
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, Yungjin Pharm reported revenue of ₩61.6bn, down 1.5% year on year, and an operating loss of ₩1.5bn. Yungjin Pharm (영진약품) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Sep 15 with 1 article. The most common catalyst was tech & capacity (1).
Yungjin Pharm quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩61.6bn | -1.5% | −₩1.5bn | −₩2.4bn |
| Q1 2026 | ₩63.8bn | -0.5% | −₩1.8bn | −₩2.3bn |
| Q4 2025 derived | ₩66.8bn | +6.3% | −₩1.1bn | −₩376m |
| Q3 2025 | ₩60.9bn | -1.9% | ₩4m | −₩1.2bn |
| Q2 2025 | ₩62.5bn | +0.5% | ₩1.9bn | ₩339m |
| Q1 2025 | ₩64.1bn | -1.3% | ₩2.6bn | ₩976m |
| Q4 2024 derived | ₩62.9bn | -2.3% | ₩1.6bn | −₩967m |
| Q3 2024 | ₩62.0bn | +4.5% | ₩1.3bn | −₩437m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Yungjin Pharm top stories 2 weeks, by number of outlets
- 1
